...I keep watching it ascend while we descend. I considered purchasing it when it was low, but did not. Maybe one day we'll have our day, but a crumb would be that at least we're partnered with them...
The Company has really gone into a cocoon at this point: recall earlier in the year how it seemed like we had announcements at a fairly regular basis. I still have faith, though, and doubt anyone will see a positive announcement coming, until it happens. All of that said, outside of executing their business plan, what can they do- outside of perhaps some insider buying?
I think India will be certainly importing a lot more coal and China's iron ore imports will also be decent. BDI will continue to recover through the end of the year, imho...
It's funny: I always thought consolidation would occur although I thought SBLK would be acquired by an 800-lb shipping gorilla- not become the acquirer!
WMS(SGMS) has a variety of Monopoly slots and seems to release a new one periodically. They'll of course preview all of their new models at this year's G2E in October, so I wouldn't be surprised to see more Monopoly but am not sure what they have for release in the short term. Great day today: strongly up even when the Market was faltering...
Nice summary: it would appear we're still in a waiting game as they execute. The delay in the stroke trial is disappointing from a cash standpoint. There was seemed to to clearly to an attempt to describe the UC trial as the longshot that it was- not that I got that impression from them while the trial was going on from them. Of course as been repeatedly discussed, maybe we should have been reading between the lines a bit more. I also don't recall RTIX relationship even being brought up: it seems likely any significant revenue from that is a long-way off.
They're still being hobbled by lack of cash/resources for some of their initiatives and given all the patents, know-how, personnel, etc, you would think they would entertain either a strategic investment or buyout from a larger entity and you would think a larger entity would be interested, but I imagine the thought of a "home run" in stroke may prevent that from occurring.
Because of the UC trial, I would imagine we'll continue to have "buying opportunities" for many months now, although I could also see something positive happening at any time. But I've been saying that for probably over a year now, so what do I know...
I think in all of the years following the Company, this will be the first time they have a call on a Monday. Of course it doesn't mean anything, unless...?
Time for some positive news guys!
It's been sooo quiet: frankly I won't believe it until it happens although at the same time, why not? They still have a lot of irons in the fire and we can literally turn on a dime. Nice move today, though: maybe some speculation from Japan?
I wasn't able to find the article and haven't re-reviewed "Louis's" article in question, although in retrospect, wasn't he correct? I really hate to say it, but isn't that the case?
My question is that if he was paid to write a negative article, who paid him and with what motivation? Was it a short-seller who feared the upcoming UC results? (hah!) Or a long who wanted more? (double-hah!)
Yes, you would think Athersys could leverage whatever works with RTI into other areas...
While I can appreciate that perspective if looking at things quickly, I really don't believe that's the way it went down. It's been repeatedly and publicly stated that the $4 capital raise was the result of current investors approaching the Company. It's inconceivable at this point to not believe that to be true. BJ made his comments after unexpectedly taking over the conference call.
I will preface this response by saying that I'm not a rookie investor but have made some rookie mistakes related to the UC-trial and the Company in general, so am still evaluating this situation and frankly licking my wounds. The hits I took were pretty hard and I'm getting to be the age were I can't responsibly take massive hits although thankfully, I've been able to pick up the slack in some other areas.
I would say I feel marginally better afterwards although realize that going in, I think I had a good understanding of the current situation. My prior mistake was really believing the UC-trial would pull through, disregarding some of the red flags in the process, and not doing a bit more research into some aspects of the trial.
I feel from an investment standpoint, the current team will work their hardest for a positive outcome, and it seems reasonable that at least one arrow from the quiver will hit the mark saving the Company from completely going south.
There is still a compelling risk/reward situation, but I'm clearly overweight in my position given that stroke is by no means a given.
I think with this Company, you are going to have to be patient, although along the way, try not to be too greedy, either.
I feel it's more risky at this point, although in retrospect, it was always more risky than most of us believed.
Thanks for the report: I would add that Mesoblast's Prochymal trial outcome may also come into play with the decision-making to move things forward for UC. If their trial is positive, then the Company and/or Pfizer would also have another reason to give it another shot, as I understand things.
No, no one brought that up. People were generally supportive in their line of questions and I don't think anyone saw the net benefit to doing so at this point.
It's my personal opinion he ultimately *does* believe that statement and maybe just got caught up in the excitement of the interview. I don't believe he went into the interview with a clear intent to pump with that statement in his back pocket. I think for a while now they're all clearly focused on stroke.
I'm honestly not sure, or if I remember correctly, but I think within the next two months or so. I could be very wrong on this. I do recall that it was mentioned that the trial is ongoing and that Pfizer can be considered a very "data driven" organization: so they will continue to collect and analyze and then make a decision on where to go from there.
I attended the meeting this morning although was a little under the weather: didn't take notes on specific comments but here are my general impressions:
1. There was an emphasis on differentiating the stroke trial from the UC trial both by design(where the Company had control versus Pfizer) and the type of disease condition(Acute versus Chronic). If you want to use the "shot on goal" analogy, consider stroke another shot, independent of the UC trial.
2. Clearly a lot of excitement regarding the potential for partnerships in Japan and Japan in general.
3. The team's morale seems to still be intact.
4. A number of people asked questions, much more than in previous meetings.
5. I caught the tail end of a follow-up, but I believe a story was mentioned regarding a patient treated with Multistem from the US was interviewed on Japanese TV: a patient who potentially received treatment before the current trial was put into place and had good results similar to the UH Youtube video that most people on this board have seen. Patients in the current trial do sign some sort of non-disclosure so you shouldn't expect people to be giving their preliminary thoughts on treatment.
6. There was some talk of the 5HT2c program and its potential benefits over the competition.
7. It seems clear now the Pfizer/UC trial was designed to be more of a "swing for the fences" trial versus a proof of concept trial which many of us may have lazily assumed it to be. I say lazily as the trial participants were people who have failed other treatments for a long time so a single dose strategy was overly optimistic although if it worked, would have been commercially viable. I suppose if we better understood this by reviewing the trial, we wouldn't have been as optimistic. That said, the Company probably could have done a better job moderating expectations, too, which I think BJ started to do on the conference call he led.
Out of characters to type, but if any questions, I'll do my best to answer.
I will most likely be able to make it although there's a chance my schedule may get complicated and I'll need to skip.
I didn't get the bottom, but reloaded at an average a bit above 11 with my average sale around 13.5 or so. I didn't expect the sell-off post earnings to miss getting in the low tens. Oh well- hopefully we'll continue upward from here!